B.Riley on Trevi Therapeutics (TRVI): 'Remain Buyers into Imminent Ph2b CORAL Readout'
Tweet Send to a Friend
B.Riley analyst Mayank Mamtani reiterated a Buy rating and $20.00 price target on Trevi Therapeutics (NASDAQ: TRVI).The analyst comments "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
